Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma

[1]  A. Ashaye,et al.  Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review , 2020, Expert review of hematology.

[2]  P. Ho,et al.  Monitoring respiratory infections in covid-19 epidemics , 2020, BMJ.

[3]  R. Trimble.  COVID-19 Dashboard , 2020 .

[4]  Diana Lagana,et al.  Bloodstream infections in neutropenic patients with haematological malignancies. , 2020, Infection, disease & health.

[5]  J. Al-Tawfiq,et al.  Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study. , 2019, Journal of infection and public health.

[6]  J. Westin,et al.  PCR Detection of Respiratory Pathogens in Asymptomatic and Symptomatic Adults , 2018, Journal of Clinical Microbiology.

[7]  C. Flowers,et al.  Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Greil,et al.  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.

[9]  R. Greil,et al.  Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma , 2017, HemaSphere.

[10]  S. Seo,et al.  Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  C. Font,et al.  Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Diehl,et al.  Treatment of Hodgkin lymphoma: the past, present, and future , 2008, Nature Clinical Practice Oncology.

[13]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[14]  L. Leibovici,et al.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. , 2005, The Cochrane database of systematic reviews.

[15]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.